NCT01285362 - Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Non-Alcoholic Fatty Liver Disease

Interventions

DRUG

Fish Oil Supplementation

Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of DHA.

DRUG

Placebo Supplementation

Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.

Trial Locations (1)

10032

Irving Clinical Research Center (GCRC) at Columbia University Medical Center, New York